Business
Ynvisible to Deliver First E-paper Displays for Medical At-Home Tests
Vancouver, British Columbia--(Newsfile Corp. - June 26, 2024) - Ynvisible Interactive Inc. ...
About this update from Ynvisible Interactive Inc. Class A
[{"type":"text","content":"Ynvisible to Deliver First E-paper Displays for Medical At-Home TestsVancouver, British Columbia--(Newsfile Corp. - June 26, 2024) - Ynvisible Interactive Inc. (TSXV: YNV) (FSE: 1XNA) (OTCQB: YNVYF) (the \"Company\" or \"Ynvisible\"), a leading provider of printed low-power e-paper display products, is pleased to announce a collaboration with a global industry leader in medical devices, to develop the next generation of medical at-home testing and diagnostic devices. The customized displays that Ynvisible developed for this application follow strict medical industry requirements, to comply with FDA regulations, and can become a standard solution in a wide range of medical and diagnostics products. Ynvisible has received a purchase order for more than 10,000 units for this new type of display, which will be delivered until the end of the year.The ultra-low-power, sustainable printed e-paper displays developed by Ynvisible can replace more traditional display technologies, working as a thinner, easier to integrate and more energy-efficient visual interface, to convey important information to the user.For the customer, switching to this innovative solution is expected to significantly increase market share over the coming years, due to the cost-effectiveness and energy efficiency of Ynvisible's e-paper displays, coupled with the advantages of roll-to-roll manufacturing.The new Ynvisible display required a high degree of customization and technological fine tuning, due to strict regulations in medical testing devices. A batch of more than 10,000 displays will be shipped until the end of the year for verification, validation, clinical testing and FDA approval. The projected order volumes for this application reach 10 million units per year. Once this device is approved by the FDA, Ynvisible anticipates additional announcements in a range of medical and diagnostic categories. This initiative validates Ynvisible's strategic focus on developing indicators designed for mass production and widespread application. To reinforce this initiative, Ynvisible is committing to targeted investments in key areas such as research and development, marketing outreach, and enhancement of production capabilities. These focused investments are set to enhance Ynvisible's product portfolio and market competitiveness, reinforcing the strategy for ...